About: Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
rdfs:seeAlso	http://ac.els-cdn.com/S0301472X14002379/1-s2.0-S0301472X14002379-main.pdf?_tid=47198962-9c81-11e4-9496-00000aab0f01&acdnat=1421304158_6115d16ef237cedb9b27da90ac0cf316
Description	Abnormalities in ATM and TP53 genes represent important predictive factors in chronic lymphocytic leukemia (CLL); however, the efficacy of CD20 targeting immunotherapy is only poorly defined in the affected patients. Therefore, we tested the in vitro response to ofatumumab (OFA) and rituximab (RTX) in 75 CLL samples with clearly defined p53 or ATM inactivation. Using standard conditions allowing complement-dependent cytotoxicity, i.e., 10 mu g/mL of antibodies and 20% active human serum, we observed clear differences among the tested genetic categories: ATM-mutated samples (n = 17) represented the most sensitive, wild-type samples (n = 31) intermediate, and TP53-mutated samples (n = 27) the most resistant group (ATM-mut vs. TP53-mut: P = 0.0005 for OFA and P = 0.01 for RTX). Abnormalities in ATM and TP53 genes represent important predictive factors in chronic lymphocytic leukemia (CLL); however, the efficacy of CD20 targeting immunotherapy is only poorly defined in the affected patients. Therefore, we tested the in vitro response to ofatumumab (OFA) and rituximab (RTX) in 75 CLL samples with clearly defined p53 or ATM inactivation. Using standard conditions allowing complement-dependent cytotoxicity, i.e., 10 mu g/mL of antibodies and 20% active human serum, we observed clear differences among the tested genetic categories: ATM-mutated samples (n = 17) represented the most sensitive, wild-type samples (n = 31) intermediate, and TP53-mutated samples (n = 27) the most resistant group (ATM-mut vs. TP53-mut: P = 0.0005 for OFA and P = 0.01 for RTX). (en)
Title	Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab (en)
skos:prefLabel	Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab (en)
skos:notation	RIV/00216224:14740/14:00078349!RIV15-MSM-14740___
http://linked.open...avai/riv/aktivita	P S
http://linked.open...avai/riv/aktivity	P(NT13519), S
http://linked.open...iv/cisloPeriodika	10
http://linked.open...vai/riv/dodaniDat	2015
http://linked.open...aciTvurceVysledku	Šrámek, Martin Jašková, Zuzana Loja, Tomáš Pospíšilová, Šárka Doubek, Michael Mayer, Jiří Malčíková, Jitka Trbušek, Martin Šebejová, Ludmila Borský, Marek Potěšil, David Navrkalová, Veronika
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Masarykova univerzita / Středoevropský technologický institut
http://linked.open...dnocenehoVysledku	11803
http://linked.open...ai/riv/idVysledku	RIV/00216224:14740/14:00078349
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	COMPLEMENT-DEPENDENT CYTOTOXICITY; P53 TUMOR-SUPPRESSOR; MONOCLONAL-ANTIBODIES; ATAXIA-TELANGIECTASIA; CD20 EXPRESSION; TP53 MUTATION; 11Q DELETION; FLUDARABINE; CHEMOIMMUNOTHERAPY; DYSFUNCTION (en)
http://linked.open.../riv/klicoveSlovo	11Q DELETION CD20 EXPRESSION COMPLEMENT-DEPENDENT CYTOTOXICITY P53 TUMOR-SUPPRESSOR DYSFUNCTION ATAXIA-TELANGIECTASIA MONOCLONAL-ANTIBODIES TP53 MUTATION CHEMOIMMUNOTHERAPY FLUDARABINE
http://linked.open...odStatuVydavatele	US - Spojené státy americké
http://linked.open...ontrolniKodProRIV	[FDA2F3C14A4E]
http://linked.open...i/riv/nazevZdroje	Experimental Hematology
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	12 (xsd:int)
http://linked.open...cetTvurcuVysledku	12 (xsd:int)
http://linked.open...vavai/riv/projekt	Early identification of CLL patients with yet unselected p53 mutation
http://linked.open...UplatneniVysledku	2014
http://linked.open...v/svazekPeriodika	42
http://linked.open...iv/tvurceVysledku	Doubek, Michael Loja, Tomáš Mayer, Jiří Pospíšilová, Šárka Malčíková, Jitka Trbušek, Martin Šebejová, Ludmila Borský, Marek Potěšil, David Šrámek, Martin Navrkalová, Veronika Jašková, Zuzana
http://linked.open...ain/vavai/riv/wos	000343791500005
issn	0301-472X
number of pages	8 (xsd:int)
http://bibframe.org/vocab/doi	10.1016/j.exphem.2014.06.003
http://localhost/t...ganizacniJednotka	14740

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 48 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software